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ABSTRACT 
Objective: The use and timing of flow diversion for aneurysmal subarachnoid hemorrhage 
(SAH) is controversial. The objective of this study is to perform a meta-analysis and 
systematic review to compare overall complication rate between early versus delayed flow 
diversion for ruptured aneurysms.  
Methods:  Literature search for all eligible articles was performed using PubMed, 
Cochrane and Web of Science databases. The primary outcome was the overall 
complication rate (any complication in the perioperative period), and secondary 
outcomes were (1) hemorrhage and (2) stroke/death (all hemorrhagic/ischemic strokes 
and/or death).  
Results:  Thirteen articles including 142 patients met inclusion criteria. Eighty-nine 
(62.7%) patients underwent early deployment of flow diverters (i.e., 2 days or less). 
The odds ratio for overall complication rate with early versus delayed flow diversion 
was 0.95 (95% CI=0.36-2.49, p=0.42). The odds ratio for the secondary outcome of 
hemorrhagic complication for early vs. delayed flow diversion was 1.44 (95% CI 0.45-
4.52, p=0.87) and of stroke/death was 1.67 (95%CI 0.5-4.9, p=0.69). The odds ratio of 
early vs. delayed flow diversion for blister/dissecting/fusiform aneurysms was 0.82 
(95% CI 0.29-2.30) and for saccular/giant aneurysms was 2.23 (95% CI 0.17-29.4). At 
last follow-up, 71.6% of patients had good performance status (mRS score 0-2), and the 
rate of angiographic aneurysm occlusion was 90.2%. 
Conclusion: This meta-analysis did not show a difference in overall complication rate 
between early vs. delayed flow diversion for ruptured aneurysms. Early flow diversion for 
ruptured blister/fusiform/dissecting aneurysms carries a lower risk of aneurysm rerupture and 
overall complications as compared to that for ruptured saccular/giant aneurysms.  
Keywords: flow diversion, ruptured aneurysm, subarachnoid hemorrhage 
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INTRODUCTION 
Subarachnoid hemorrhage (SAH) from a ruptured intracranial aneurysm occurs with an 
incidence of 6-8 per 100,000 in the western population.1–3 The International Subarachnoid 
Aneurysm Trial (ISAT)1 and the Barrow Ruptured Aneurysm Trial (BRAT)4 provided Level 1 
evidence for the safety and efficacy of both endovascular coiling and neurosurgical clipping. 
Some types of aneurysm morphologies—including giant, dissecting, fusiform and blister—are 
considered “challenging” because they are difficult to treat by conventional endovascular or 
neurosurgical means. For example, neurosurgical treatment of a fusiform aneurysm may require 
trapping and bypass, which carries inherent morbidity. Similarly, endovascular treatment of a 
blister aneurysm may not be amenable to primary coiling and may require stent or balloon 
assistance.  
In recent years, flow diversion has emerged as a viable endovascular treatment option for 
unruptured aneurysms with “challenging” morphologies.5,6 Flow diversion obviates the need for 
neurosurgical bypass by placing a stent with high metal coverage across the aneurysmal segment 
of an intracranial vessel.7 Stasis of blood flow within the aneurysm sac leads to aneurysm 
thrombosis.8 Over time, neointimal proliferation incorporates the stent within the vessel’s 
endothelium and removes the aneurysm from the circulation.9  
The use of flow diversion for ruptured aneurysms, unlike that for unruptured aneurysms, is 
controversial and has two main concerns.10 First, to prevent thromboembolic complications, 
flow-diverting stents require antiplatelet medications, which may exacerbate bleeding in SAH 
and increase the risk of hemorrhagic complications from additional procedures (such as 
ventriculostomy to relieve hydrocephalus).11 Second, flow diversion results in delayed aneurysm 
occlusion, which may increase the risk of aneurysm rerupture in the acute phase of SAH.12 
Despite these concerns, a number of retrospective case series have presented their experience 
with flow diversion to treat ruptured aneurysms with “challenging” morphologies.13–23 These 
case series have justified the use of flow diversion as a salvage treatment for ruptured aneurysms 
with “challenging” morphologies, which are difficult to treat by traditional neurosurgical or 
endovascular modalities.23,24  
Once a decision is made to treat a ruptured aneurysm with flow diversion, there is considerable 
debate on the ideal timing of flow diverter placement. Some experts recommend early flow 
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diversion (less than 2 days from SAH ictus),19,21,25 while others advocate for delayed treatment 
(2-14 days from SAH ictus).18,26 The stated reasons for timing of flow diversion are anecdotal; 
for example, some prefer early flow diversion because it may facilitate faster patient 
rehabilitation, while others prefer delayed flow diversion because it may minimize hemorrhagic 
complications from dual antiplatelet therapy. However, there are no published data comparing 
the safety profile of early versus delayed flow diversion for ruptured aneurysms. Therefore, the 
current study presents results from a meta-analysis comparing the overall complications 
associated with early vs. delayed flow diversion for ruptured aneurysms.  
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METHODS 
A systematic review and meta-analysis was performed to compare the complication rates 
associated with early vs. delayed flow-diverter treatment of ruptured intracranial aneurysms. The 
Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA)27 protocol was 
followed to perform the literature search, to determine the inclusion and exclusion criteria, and to 
select the appropriate statistical methods.  
Literature search  
A detailed literature search was performed from three electronic databases—PubMed, Cochrane 
Library and the Web of Science—from January 2010 to February 2018. All published articles 
and abstracts were searched in both English and non-English languages using the key terms 
“flow diverter”, “pipeline”, “stent”, “aneurysms”, “ruptured”, “subarachnoid hemorrhage” and 
their synonyms using [AND] and/or [OR] connectors. An Internet search was also performed to 
look for any unpublished literature. Three investigators (RHD, DPP, RM) independently 
performed the primary search, reviewed the titles of the articles, and removed duplicated articles. 
Then, the full text of each article reviewed by two investigators (RHD, RM) to identify suitable 
studies to be included in the analysis. Any discrepancy in selection of studies and data collection 
was clarified by mutual consensus.  
Inclusion and exclusion criteria  
All studies describing outcomes after flow-diverter treatment of ruptured aneurysms were 
reviewed. Case reports and case series with fewer than 5 patients were excluded. The most 
important inclusion criteria was the notation of exact timing (in days) of flow-diverter treatment 
following subarachnoid hemorrhage. Other inclusion criteria included mention of morbidity 
(procedural, hemorrhagic, or ischemic complications) and mortality. Studies describing flow 
diversion as a staged procedure (for example, after initial coiling of ruptured aneurysm) were 
excluded. Studies with overlapping cohorts of patients were screened, and the latest published 
article or the article with higher number of patients was selected. Age, race, country of origin 
were not factors for exclusion. Corresponding authors were contacted by email and phone to 
account for missing data in eligible manuscripts.    
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Outcome measures and definitions 
Timing of flow-diverter treatment was categorized as “Early” if it occurred within the first 2 
days following SAH or “Delayed” if it was more than 2 days. The primary outcome was the 
“Overall complication rate,” which included any complication in the perioperative period. 
Secondary outcomes were “Stroke/Death,” which included all hemorrhagic/ischemic strokes 
and/or death, and “Hemorrhage,” which included only hemorrhagic strokes. Multiple predictive 
factors were correlated with the primary outcome, including the age of the patient (≤ 60 years vs. 
>60 years), aneurysm type (blister/dissecting/fusiform vs saccular/giant) and aneurysm location 
(anterior vs. posterior circulation).  
Assessment of study quality, bias and study heterogeneity 
Two reviewers independently reviewed the full text of each article to eliminate selection bias. 
Study quality was evaluated using the Quality Assessment Tool for  case series  studies from the 
National Heart, Lung, and Blood Institute (NHLBI), which comprises  9 criteria/questions.28 A 
study was considered to be of good quality if it met at least  7 of the 9 criteria, “fair” if it met  4-
6 criteria, and “poor” if met 3 or less  . Publication bias for the primary and secondary outcome 
was evaluated using Funnel plots, and the significance of asymmetry along with tests for small 
study effects (H0) was assessed with Eggers test using mixed effects meta-regression model. 
Study heterogeneity was evaluated with Cochran Q test and I2.  
Statistical methods 
1. Individual Participant Data (IPD) Meta-analysis 
We implemented the Individual Participant Data (IPD) meta-analysis29 to review both the 
primary and secondary outcomes of individual patients in early vs. delayed treatment groups in 
each of the included studies. In IPD meta-analysis, individual patient data is pooled while 
preserving the clustering of patients within each study. In comparison to traditional meta-
analysis, IPD meta-analysis allows both study-level and patient-level interactions.29 For example, 
in this study, the IPD meta-analysis allowed us to perform subgroup analyses for overall 
complications in the early vs. delayed treatment groups based on patient age, and location and 
type of aneurysm.  
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We performed a two-staged IPD meta-analysis using the “IPDMETAN” module in the STATA 
software (Statacorp, USA, version 15.1) using the collapse-based syntax. Pooled estimates of 
odds ratios with 95 percent confidence interval were calculated using Mantel-Haenszel method 
for both the primary and secondary outcomes. A fixed model was used due to low level of 
heterogeneity among the studies. Forest plots were created to combine data from all included 
studies and to calculate a pooled summary of all data. L'Abbé plots were drawn to observe the 
complication risks with early vs. delayed treatment and to explore the heterogeneity of effect 
estimates within the meta-analysis using the STATA module “METAN”.  Subgroup analysis 
with meta-regression was conducted from the summary estimates to identify potential 
moderators of overall complication rate with a restricted maximum likelihood estimator of the 
variance of the true effect. The moderators that were analyzed to affect the variability in effect 
sizes included the patient label characteristics like age, location and type of aneurysm.  
2. Proportion Meta-Analysis 
A limitation of the IPD meta-analysis in this review was the small number of studies (7) 
including patients in both early and delayed treatment cohorts. Of the 13 studies meeting 
inclusion criteria, 6 studies were not included in the IPD meta-analysis because all patients in 
each of these 6 studies received either early or delayed flow-diverter treatment. Therefore, to 
overcome this limitation, we additionally performed a meta-analysis of proportions30 by pooling 
patients in the early vs. delayed treatment groups. This meta-analysis of proportions allowed us 
to increase the sample size and to calculate odds ratios with increased power.  
The meta-analysis of proportions was performed using the METAPROP module of STATA 
software (Statacorp, USA, version 15.1).30 A fixed model was used to calculate the pooled 
estimates after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Meta-
regression analysis was performed to compare the estimates between early vs. delayed treatment 
groups.    
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RESULTS 
Study characteristics  
The initial database search identified 1482 articles after accounting for duplicate titles. Full texts 
of 55 articles were reviewed for eligibility. Finally, 13 articles13,14,17–26,31 meeting inclusion 
criteria were selected for data archival and analysis. Individual patient data was retrieved from 
each of the 13 studies. Seven studies were included in the Individual Participant Data (IPD) 
meta-analysis because these studies had patients with complications in both the early and 
delayed treatment groups, and were therefore directly comparable to each other. To account for 
limitations in the IPD meta-analysis, a traditional Proportion meta-analysis was also performed, 
which included all 13 studies. The details of the (Preferred Reporting Items for Systematic 
Reviews and Meta-analysis) PRISMA protocol are depicted in Figure 1.  
Patient characteristics  
Summary characteristics for each of the 13 included studies are listed in Table 1. The number of 
patients included from each study ranged from 5 to 18, for a combined total of 142 patients. The 
mean patient age was 53.7 years. The timing of intervention from presentation with SAH to flow 
diversion was early (2 days or less) in 89 (62.7%) patients and delayed in 53 (37.3%), with an 
average time to treatment of 4.2 days (range 3-26days). The mean aneurysm size was 6mm. The 
vast majority of patients (117/142, 82.3%) with SAH treated with flow diversion had ruptured 
fusiform (12/142, 8.5%), dissecting (46/142, 32.4%) or blister (59/142, 41.5%) aneurysms, 
which are not amenable to coil placement. As a result, adjunctive coiling along with flow 
diversion was used in a minority of patients (16/142, 11.3%). Aneurysms treated with flow 
diversion were located in the anterior circulation in 60.6% (86/142) of patients, and were located 
in the posterior circulation in 39.4% (56/142). In the majority of studies (n=9), the pre-procedure 
antiplatelet regimen of choice was 600mg clopidogrel and 300mg/625mg aspirin. Pipeline 
embolization device (PED; Medtronic, Irvine, California, USA) was the only flow diverter used 
in 10 studies, SILK flow diverter (SFD; Balt Extrusion, Montmorency, France) was the only 
flow diverter used in 2 studies, and one study used PED, SFD and Surpass (Surpass; Stryker 
Neurovascular, Fremont, California, USA) flow diverters (Table 1). The demographic and 
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clinical characteristics of the patients in the early and delayed treatment groups have been 
summarized in Table 2.  
Complications 
None of the aneurysms reruptured prior to treatment with flow diversion. Aneurysm rerupture 
occurred in 5 patients (3.5%), and the mortality rate for these 5 patients was 100%. The 
aneurysm size was larger than 2cm in 60% (3/5) of reruptured aneurysms. In the entire patient 
series, the rerupture rate of all aneurysms larger than 2cm was 42.9% (3/7), while the rerupture 
rate of all aneurysms smaller than 2cm was 1.9% (2/107). The morphology of reruptured 
aneurysms was saccular in 40% (2/5) and fusiform in 60% (3/5). Aneurysms that reruptured 
were treated during the early phase in 100% (5/5) of cases. In 60% of cases (3/5), the aneurysm 
reruptured intraoperatively during or immediately following deployment of flow diverter; the 
other 2 reruptures occurred on post-procedure day 1 and 8. Adjunctive coiling along with flow 
diversion was utilized to treat only one of these ruptured aneurysms (20%, 1/5). The rate of 
aneurysm rerupture with flow diversion alone was 3.3% (4/122) and with flow diversion + 
adjunctive coiling was 5.6% (1/18).  
Hemorrhagic complications other than aneurysm rerupture occurred in 12% of patients (17/142), 
5 of which led to mortality. Of these hemorrhagic complications, 6 occurred from placement of 
an external ventricular drain (EVD), and other hemorrhages occurred in disparate locations, 
including spinal epidural hematoma (1), vitreous hemorrhage (1), worsening intraventricular 
hemorrhage (1), hemorrhagic infarct (2), cerebellar hematoma (1), frontal intraparenchymal 
hematoma (1), among others. Ischemic complications occurred in 7% (10/142) of cases, 2 of 
which led to mortality (brainstem ischemia and large middle cerebral artery infarction). 
Procedure-related complications occurred in 17 patients (12%).  
The overall mortality rate was 15.5% (22/142), and the overall complication rate was 27.5% 
(39/142). 
Clinical and angiographic outcomes 
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The overall percentage of patients with good performance status (mRS score of 0-2) following 
flow diversion for ruptured aneurysms was 71.6% (101/141). The rate of angiographic occlusion 
of ruptured aneurysms treated with flow diversion at last follow-up was 90.2% (101/112).   
Meta-analysis 
1. Individual Participant Data Meta-Analysis  
The odds ratio for overall complication (primary outcome) rate for early vs. delayed flow 
diversion was 0.95 (95% CI 0.36-2.49, Cochran Q statistic p=0.42). However, the odds ratio for 
secondary outcomes of hemorrhagic complication for early vs. delayed flow diversion was 1.44 
(95% CI 0.45-4.52, Cochran Q statistic p=0.87) and of stroke/death for early vs. delayed flow 
diversion was 1.67 (95%CI 0.5-4.9, Cochran Q statistic p=0.69). In summary, the results indicate 
no difference in overall complication rate between early vs. delayed flow diversion, but a higher 
(although not statistically significant) risk for hemorrhagic complications and for stroke/death in 
the early group (Figure 2). The L'Abbé plots for the primary and secondary outcomes show that 
3 studies had higher risk for overall complication with early treatment, 4 studies had higher risk 
for hemorrhage with early treatment, and 4 studies had higher risk for stroke/death with early 
treatment (Figure 3).  
We performed a subgroup analysis of odds ratios for overall complications in the early vs. 
delayed treatment groups based on patient age, aneurysm location and aneurysm morphology 
(Figure 4). The odds ratio of early vs. delayed flow diversion was 1.39 (95% CI 0.48-4.00) for 
patients ≤60 years and 0.55 (95% CI 0.09-3.48) for patients >60 years, but the difference in odds 
ratios was not statistically significant (Cochran Q statistic p=0.44). The odds ratio of early vs. 
delayed flow diversion was 0.82 (95% CI 0.29-2.30) for blister/dissecting/fusiform aneurysms 
and 2.23 (95% CI 0.17-29.4) for saccular/giant aneurysms, but the difference in odds ratios was 
not statistically significant (Cochran Q statistic p=0.43). Finally, the odds ratio of early vs. 
delayed flow diversion was 1.62 (95% CI 0.5-4.9) for patients with anterior circulation 
aneurysms and 0.28 (95% CI 0.05-1.65) for patients with posterior circulation aneurysms, but the 
difference in odds ratios was not statistically significant (Cochran Q statistic p=0.14).   The 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Dossani 10 
 
 
meta-regression with bubble plots further demonstrate that the differences in summary estimates 
between the subgroups were not statistically significant (Figure 5).  
2. Proportion meta-analysis:  
11 studies (with 92 patients) reported outcomes on early flow-diverter treatment, whereas 10 
studies (with 53 patients) reported outcomes on delayed flow-diverter treatment. The pooled 
percentage of overall complication rate was 33% (95% CI 0.22-0.44) in the early treatment group 
and 22% (95% CI 0.10-0.37) in the delayed treatment group (Figure 6). The pooled percentage 
of hemorrhage was 14% (95 CI-0.06, 0.23) in the early treatment group and 5% (95% CI-0.00-
0.15) in the delayed treatment group. Finally, the pooled percentage of stroke/death was 29% 
(95% CI 0.18-0.40) in the early treatment group and 11% (95% CI 0.02-0.24) in the delayed 
treatment group. Meta-regression between the two groups did not identify any significant 
difference of proportions for overall complication, hemorrhage or stroke/death (Figure 7).  
Quality of studies and Bias assessment 
Most studies scored “fair” in the National Heart, Lung and Blood Institute (NHLBI) Quality 
Assessment Tool for observational studies. Funnel tests for outcome parameters did not show 
any significant publication bias.  
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DISCUSSION 
Impact of timing of flow diversion on overall complication rate 
This meta-analysis of 13 studies analyzing the use of primary flow diversion (i.e. without prior 
coiling or adjunctive aneurysm treatment) for ruptured aneurysms did not find a statistically 
significant difference in the overall complication rate (primary outcome) between the early or 
delayed treatment groups (OR=0.95, 95% CI 0.36-2.49, Cochran Q statistic p=0.42). However, 
with respect to the secondary outcomes of hemorrhage and stroke/death, the results demonstrated 
a higher (although not statistically significant) risk of hemorrhagic complications (OR=1.44, 
95% CI 0.45-4.52, Cochran Q statistic p=0.87) and of stroke/death (OR=1.67, 95% CI 0.5-4.9, 
Cochran Q statistic p=0.69) in the early group.  It is important to note that the objective of this 
study was not to evaluate the overall safety of flow diversion for ruptured aneurysms but to 
evaluate whether timing of flow diversion for ruptured aneurysms has an impact on the overall 
complication rate. Therefore, the overall results of the meta-analysis suggest that the timing of 
flow diversion does not impact the overall complication rate and that the risk of hemorrhagic 
complications and of stroke/death is slightly higher with early flow diversion.  
Flow diversion for ruptured aneurysms carries inherent risks: (1) flow diversion leads to delayed 
aneurysm occlusion, and therefore there is a risk for aneurysm rerupture; and (2) dual antiplatelet 
therapy may exacerbate bleeding from SAH and from necessary procedures (central venous 
catheters, ventriculostomies, ventriculoperitoneal shunting, etc.). Ideally, ruptured aneurysms 
should be secured as soon as possible following SAH without the use of antiplatelet therapy. 
However, certain aneurysm morphologies (such as giant, blister, fusiform or dissecting) are 
considered “challenging” because they are difficult to treat with conventional endovascular or 
neurosurgical modalities. Conventional endovascular treatment options for these “challenging” 
aneurysms include reconstructive (e.g. balloon-stent assisted coiling) and deconstructive (e.g. 
parent vessel sacrifice) treatments,32 while conventional neurosurgical treatments include 
aneurysm wrapping or trapping with bypass. Often, in treating “challenging” ruptured 
aneurysms, these conventional endovascular or neurosurgical treatments are not possible or are 
associated with high rates of perioperative morbidity and mortality.33 Flow diversion has 
therefore emerged as a viable treatment option for such “challenging” aneurysms. Accordingly, 
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the issue of timing of flow diversion following SAH is most applicable in the treatment of 
“challenging” ruptured aneurysms. The following section discusses the relationship between 
morphology of “challenging” ruptured aneurysm and timing of flow diversion on overall 
complication rate.  
Relationship between ruptured aneurysm morphology and timing of flow diversion on 
overall complication rate  
The subgroup analysis of “challenging” ruptured aneurysm morphology favored (OR=0.82, 95% 
CI=0.29-2.30) early treatment for ruptured blister, fusiform or dissecting aneurysms, but did not 
favor (OR=2.23, 95% CI=0.17-29.4) early treatment of giant saccular aneurysms, although the 
difference in odds ratios was not statistically significant (Cochran Q statistic p=0.43). In 
addition, of the 5 aneurysms that reruptured in the entire systematic review, the morphology was 
saccular in 40% (2/5) and the rerupture rate was 42.9% (3/7) for all aneurysms larger than 2cm. 
More importantly, all aneurysm reruptures occurred during the early treatment phase and carried 
a mortality of 100% (5/5). These data from both the subgroup meta-analysis and the systematic 
review suggest significant risks for flow diversion in the early treatment group for saccular 
aneurysms that are larger than 2cm.  
Given the high risk of rerupture and subsequent mortality from primary flow diversion for large, 
saccular ruptured aneurysms, a new endovascular treatment paradigm of acute coiling followed 
by staged flow diversion appears to be a safer endovascular option for these ruptured aneurysms. 
34
 Brinjikji et al. reported results for acute coiling followed by delayed flow diversion (median 
time of 16 weeks between the coiling and flow diversion) in 27 patients who had SAH from 
large/giant ruptured aneurysms. One patient developed rerupture after coiling but before flow 
diversion. At last follow up, 18 patients had complete or near complete aneurysm occlusion, and 
25 patients had good performance status (mRS score 0-2).34 The excellent results reported in this 
study are likely due to the reduced risk of hemorrhagic complications—especially aneurysm 
rerupture—from dual antiplatelet therapy for delayed flow diversion for large/giant saccular 
ruptured aneurysms.  
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On the other hand, as demonstrated by this meta-analysis, the safety profile of early flow 
diversion for ruptured blister, dissecting, or fusiform aneurysms is more favorable than that for 
ruptured giant saccular aneurysms, although the difference was not statistically significant. 
Perhaps it is fortuitous that blister, dissecting or fusiform aneurysms are more favorable to treat 
in the early phase with flow diversion because, unlike giant saccular aneurysms, these aneurysms 
are not amenable to primary coil embolization. From an open neurosurgical approach, blister, 
fusiform and dissecting aneurysms require a combination of aneurysm wrapping, aneurysm 
trapping and bypass or parent vessel sacrifice, all of which are associated with high procedural 
morbidity. There is evidence that endovascular approaches are superior to neurosurgical 
approaches in the treatment of blister, fusiform and dissecting aneurysms. A meta-analysis 
comparing a variety of neurosurgical and endovascular treatments for ruptured blister aneurysms 
concluded that endovascular treatments were associated with lower morbidity and mortality as 
compared to neurosurgical approaches.32 A series of 5 patients with ruptured blister aneurysms 
treated with flow diversion demonstrated favorable performance status (mRS 0-2) in all 5 
patients with aneurysm occlusion rate of 100%.24 Lin et al. published a series of 26 ruptured 
aneurysms treated with flow diversion, 8 of which had blister morphology; all 8 patients had 
complete aneurysm occlusion at last followup and 7/8 patients had a good outcome.25 In both of 
the above case series, the timing of intervention (early vs. delayed) did not influence clinical 
outcomes or angiographic occlusion rates. 
Limitations 
The chief limitation of this meta-analysis is the small number of included studies (n=13) with 
small sample size of comparison groups, which reflects the lack of data published on flow 
diversion for ruptured aneurysms. The Individual Participant Data (IPD) meta-analysis included 
only 7 studies. To overcome the limitations of the IPD meta-analysis, a Proportion meta-analysis 
including all 13 studies was performed. Both IPD and proportion meta-analyses incorporated 
case series performed at different institutions. Therefore, the conclusions of the meta-analyses 
are limited by differences in institutional protocols for flow diversion for ruptured aneurysms 
(e.g. choice of antiplatelet regimen and timing of flow diversion following SAH). An important 
limitation of the current meta-analysis is the nature of the studies. All the included studies are 
case series and do not include any experimental arm pertinent to our research question. Similarly, 
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the individual patient data collected for our analysis are derived from the published series in 
which the patients were not treated with a predefined protocol and therefore include a significant 
diversity. Therefore, the results of this meta-analysis may not serve as a strong evidence 
regarding formulating or modifying treatment guideline, but can possibly serve as a baseline 
research for future large-scale randomized studies.   
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CONCLUSIONS 
Flow diversion for ruptured intracranial aneurysms is safe and effective in achieving aneurysm 
occlusion and favorable patient outcomes. This meta-analysis did not show a difference in 
overall complication rate (primary outcome) between early vs. delayed flow diversion for 
ruptured aneurysms.  However, clinical judgment is paramount in selecting patients with 
ruptured aneurysms for treatment with flow diversion. Early flow diversion for ruptured 
blister/fusiform/dissecting aneurysms carries a lower risk of aneurysm rerupture and overall 
complications as compared to that for ruptured saccular/giant aneurysms. Randomized controlled 
trials comparing flow diversion to standard treatment for ruptured aneurysms will further 
elucidate the safety and efficacy of flow diversion for ruptured aneurysms.  
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FIGURE LEGENDS 
Figure 1: Selection process for included studies using Preferred Reporting Items for Systematic 
Reviews and Meta-analysis (PRISMA) protocol  
Figure 2: Forest plots from Individual Participant Data (IPD) meta-analysis showing the pooled 
odds ratios with 95% confidence intervals for overall complication (A), hemorrhage (B) and 
Stroke/Death (C). MH Q statistics: Cochran Q statistics using Mantel-Haenszel method.  
Figure 3: L'Abbé plots showing the risk of overall complication (A), hemorrhage (B) and 
stroke/death (C) as seen in individual studies. The size of the circles represents the sample size. 
The solid line represents the estimated overall odds ratio. The dashed line represents the line of 
no-effect.  
Figure 4: Forest plots showing subgroup analysis for moderators including age, type of aneurysm 
and location of the aneurysm. MH Q statistics: Cochran Q statistics using Mantel-Haenszel 
method 
Figure 5: Meta-regression analysis with bubble plots showing difference in summary estimates 
by different moderators, age (A), type of aneurysm (B), Location of the aneurysm (C). The solid 
line represents regression line.  
Figure 6: Forest plots from proportion meta-analysis showing pooled proportions of overall 
complication, hemorrhage and stroke/death with early and delayed treatment.  
Figure 7: Meta-regression analysis with bubble plots showing difference in summary estimates 
for overall complication (A), hemorrhage (B) and stroke/death (C) between early and delayed 
treatment. The solid line represents regression line.  
Figure 8: Funnel plots for publication bias in reporting overall complication, hemorrhage and 
stroke/death.  
TABLE LEGENDS 
Table 1: Summary of characteristics for each of the included studies 
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Table 1: Summary of characteristics for each of the thirteen included studies. 
 
NR-Not reported 
1
 Numbers in parentheses denote excluded patients due to previous treatment or no flow diverter used
 
 
2
 Aneurysm occlusion rates calculated from available data
 
 
3
 Favorable outcome = mRS scale 0-2 or Glasgow Outcome Score 4-5
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Table 2: Demographic and clinical characteristics between two treatment arms 
 
Characteristic 
Early Treatment 
Group 
(n=89) 
Delayed treatment 
Group 
(n=53) 
p-value 
Age (Mean) 55.2 51.8 0.18 
Size (in mm) 6.8 4.7 0.04 
Type of aneurysm 
Blister / Dissecting / 
Fusiform aneurysm 
76 41 
0.25 
Saccular aneurysm 13 12 
Location of the 
aneurysm 
Anterior circulation 46 41 
0.002 Posterior 
circulation 
43 12 
Presentation grade 
Good grade (WFNS 
1-2) 
40 40 
0.004 
Poor grade (>3) 49 13 
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ABBREVIATIONS 
 
SAH: subarachnoid hemorrhage 
ISAT: International subarachnoid aneurysm trial 
BRAT: Barrow Ruptured Aneurysm Trial 
NHLBI: National Heart, Lung, and Blood Institute 
IPD: Individual Participant Data 
PED: Pipeline Embolization Device 
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analysis 
 
